$300.14▾ 0.80%
End-of-day close · 2026-08-06
What most investors miss
Trends, drivers and alerts — the full picture.
Profit → Cash
$0.80cash per $1 profit
Healthy
Most of its reported profit shows up as real cash.
Valuation
45th pctvs its own history
Fair
Its valuation is around the middle of its own recent range.
Revenue growth
+14.1%year over year
Healthy
Revenue is growing at a steady pace.
Leverage
Not enough data yet
Term-debt data is not available for this company.
More coming: dilution / share-count creep.
Fair value
Overvalued
Trading about 62% above our fair-value range
A cash-flow (DCF) estimate cross-checked against peer multiples.
✦ The read
Ligand Pharmaceuticals Incorporated turns 80¢ of every reported profit-dollar into real cash. Most of its reported profit shows up as real cash. Revenue is growing at a steady pace. Its valuation is around the middle of its own recent range.
Key numbers
Valuation
EPS (TTM)$7.43
TTM (trailing 12 months, through fiscal Q1 FY2026)
Profitability
Net margin55.9%
TTM (trailing 12 months, through fiscal Q1 FY2026)
Size
Revenue (TTM)$274.48M
TTM (trailing 12 months, through fiscal Q1 FY2026)
Recent news
Sentiment · last 30 days1 article
1 bullish0 neutral0 bearish
3 Overlooked Stocks Positioned for the Next Market Rotation
CRISPR Therapeutics vs. Viking Therapeutics: Which Healthcare Stock Is a Better Buy in 2026?
XOMA Royalty Corporation Declares Quarterly Preferred Stock Dividend and Announces Redemption of Its Perpetual Preferred Stock and CVR Dividend Record DateLigand Announces 2026 Investor Day in New York City
Signals and key numbers are from the fiscal Q1 FY2026 filing. Price freshness: end-of-day close on Free, 15-min delayed on Pro.